+612 9045 4394
Management of Nausea and Vomiting in Cancer and Cancer Treatment - Paul J. Hesketh

Management of Nausea and Vomiting in Cancer and Cancer Treatment

Paperback Published: 1st November 2004
ISBN: 9780763731397
Number Of Pages: 256

Share This Book:


or 4 easy payments of $93.49 with Learn more
Ships in 7 to 10 business days

For all cancer professionals interested in minimizing treatment-induced complications for their patients, this volume provides the most up-to-date overview of the topic currently available. This book provides a comprehensive overview of the extent of this problem, the types of nausea and vomiting arising from cancer treatment, a review of pathophysiologic mechanisms and predictive factors, and options available for treatment strategies.

Prefacep. xi
Contributorsp. xiii
Acknowledgmentsp. xv
Management of Nausea and Vomiting in Cancer Treatment: Introduction, Scope of the Problemp. 1
Introductionp. 1
Emetic Syndromesp. 3
Acute Emesisp. 3
Delayed Emesisp. 4
Anticipatory Emesisp. 4
Unique Aspects of Nauseap. 4
Predictive Factorsp. 5
Magnitude of the Current Problem with CINVp. 5
Remaining Challengesp. 7
Summaryp. 9
Referencesp. 9
Mechanisms of Acute, Delayed, and Anticipatory Emesis Induced by Anticancer Therapiesp. 15
Introductionp. 15
Cave to Clinic: Nausea and Vomiting in an Evolutionary Contextp. 16
Overview of the Neurophysiology of Nausea and Vomitingp. 18
Pathways for the Induction of Nausea and Vomitingp. 18
Motor Outputsp. 21
Nauseap. 23
Integration of Inputs and Coordination of Outputsp. 26
Mechanisms of Acute and Delayed Nausea and Vomiting Induced by Anticancer Therapiesp. 27
Acute Nausea and Vomiting Induced by Anticancer Therapiesp. 29
Pharmacology of Antiemetics in the Acute Phasep. 36
5-HT[subscript 3] Receptor Antagonist "Failures"p. 36
Actions of Dexamethasonep. 38
Delayed Nausea and Vomiting Induced by Anticancer Therapiesp. 38
Terminologyp. 39
Acute and Delayed Relationshipp. 39
Pathways and Mechanisms of Delayed Emesisp. 40
Patient Factorsp. 41
Is 5-HT Involved in Delayed Emesis and Are There Any Lessons To Be Learned from Neurochemical Studies During Acute Emesis?p. 42
Role of Substance Pp. 43
Glucocorticoids and ACTH Mimeticsp. 44
Other Neurotransmitter Pathwaysp. 46
Peripheral Nerve Lesions Antagonize But Fail to Prevent Delayed Emesisp. 47
Anticipatory Nausea and Vomiting (ANV) Induced by Anticancer Therapiesp. 48
Future Directionsp. 50
Referencesp. 51
Methodological Issues in the Assessment of Nausea and Vomitingp. 67
Introductionp. 67
Measuring Emesisp. 69
Vomitingp. 69
Nauseap. 70
Mixed Responsesp. 71
Patient Populationp. 72
Study Designp. 73
Randomized Parallel Designp. 74
Crossover Designp. 74
Comparisonsp. 74
Efficacy Evaluationp. 75
Unifactorial Analysis of Acute Emesisp. 76
Multifactorial Analysis of Acute Emesis at First Cycle of Chemotherapyp. 76
Multifactorial Analysis of Acute Emesis in Subsequent Cycles of Chemotherapyp. 77
The Relationship Between Nausea and Vomitingp. 80
Analysis of Delayed Emesisp. 82
Conclusionsp. 83
Referencesp. 83
The Role of Prognostic Factors in Chemotherapy-Induced Nausea and Vomitingp. 87
Introductionp. 87
Prognostic Factors for Acute CINVp. 88
Major Patient-Related Factorsp. 88
Minor Patient-Related Factorsp. 89
Chemotherapy-Related Factorsp. 91
Genetic Polymorphismsp. 94
Prognostic Factors for Delayed CINVp. 95
Future Directionsp. 95
Referencesp. 96
Impact of Nausea and Vomiting on Health-Related Quality of Lifep. 99
Introductionp. 99
Health-Related Quality of Lifep. 100
Definition of HRQOLp. 100
What HRQOL Assessments Measurep. 101
How HRQOL Assessment is Carried Outp. 102
Types of HRQOL Questionnairesp. 102
Questionnaires for Measuring HRQOL After CINVp. 103
When to Collect HRQOL Datap. 105
Analysis and Interpretation of HRQOL Data in CINVp. 105
HRQOL Risk Factors for CINVp. 106
Effects of CINV on HRQOLp. 107
The Importance of Completely Preventing CINVp. 111
Summary and Conclusionsp. 112
Referencesp. 113
A Biobehavioral Perspective of Nausea and Emesisp. 119
Introductionp. 119
A Biobehavioral View of the Causes of Nausea and Vomitingp. 121
Role of the Autonomic Nervous System in Nausea and Vomitingp. 123
Evidence that the Hypothalamic Pituitary Adrenal (HPA) Axis is Involved in the Development of Nauseap. 124
Evidence that Patient Expectation Can Influence the Development of Nauseap. 126
Phases of Chemotherapy-Induced Nausea and Emesisp. 129
Anticipatory Nausea and Vomiting (ANV)p. 129
Post-Treatment Nausea and Vomitingp. 130
Pharmacologic Treatment of Nausea and Vomitingp. 132
Behavioral Treatment of Nausea and Vomitingp. 134
Progressive Muscle Relaxation Trainingp. 134
Systematic Desensitizationp. 135
Hypnosisp. 135
Cognitive Distractionp. 136
Biofeedbackp. 136
Referencesp. 137
Integrated Therapy of Nausea and Vomitingp. 147
Introductionp. 147
Ranking of Emetogenicityp. 147
Antiemetic Guidelinesp. 148
Effectiveness of Guidelinesp. 150
Limitations of Guidelinesp. 151
Cannabinoids and Opiatesp. 152
Natural Products: Gingerp. 153
Non-Pharmacologic Interventionsp. 154
Conclusionsp. 155
Referencesp. 156
Serotonin-Receptor Antagonistsp. 161
Introductionp. 161
Acute and Delayed Nausea and Vomitingp. 162
Highly Emetogenic Chemotherapy: Acute Controlp. 162
Highly Emetogenic Chemotherapy: Delayed Controlp. 164
Moderately Emetogenic Chemotherapy: Acute Controlp. 166
Moderately Emetogenic Chemotherapy: Delayed Controlp. 167
Discussionp. 171
Referencesp. 173
Persistent Problems in Emesis Controlp. 181
Introductionp. 181
Unsatisfactory Control of Delayed Emesisp. 182
Measuring Nausea and its Impact on Daily Lifep. 184
Crossover Between 5-HT[subscript 3] Antagonists in Acute Emesis Failurep. 185
Antiemetic Efficacy of 5-HT[subscript 3] Antagonists is Not Maintained Over Repeated Cyclesp. 186
Controlling Delayed and Anticipatory Emesisp. 190
Conclusionsp. 191
Referencesp. 191
Radiation-Induced Emesisp. 197
Introductionp. 197
Pathogenesisp. 198
Who is At Risk of Radiation-Induced Emesis?p. 198
What is Optimal Therapy?p. 202
Duration of Therapyp. 204
Conclusionsp. 206
Referencesp. 207
Substance P Antagonistsp. 211
Introductionp. 211
Tachykinins and the Pathophysiology of Emesisp. 211
Preclinical Studiesp. 213
Clinical Studiesp. 214
Phase II Studiesp. 215
Phase III Studiesp. 219
Drug-Drug Interactionsp. 220
Adverse Effectsp. 222
Conclusionsp. 223
Referencesp. 225
Further Improvement in the Control of Chemotherapy-Induced Nausea and Vomiting: Future Directionsp. 231
Introductionp. 231
Ensuring the Use of Current Best Treatment Approachesp. 233
Better Defining Higher-Risk Patient Subsets and Achieving a Better Understanding of the Mechanisms of Failurep. 235
Novel Approaches with Existing Agentsp. 236
Serotonin Antagonistsp. 236
NK[subscript 1] Antagonistsp. 236
Complementary Approachesp. 237
Evaluation of New Agentsp. 238
5-Hydroxytryptamine Receptor Modulatorsp. 238
Broad Spectrum Receptor Antagonistsp. 239
Cannabinoidsp. 239
Other Agentsp. 240
Conclusionsp. 240
Referencesp. 241
Indexp. 247
Table of Contents provided by Rittenhouse. All Rights Reserved.

ISBN: 9780763731397
ISBN-10: 0763731390
Audience: Professional
Format: Paperback
Language: English
Number Of Pages: 256
Published: 1st November 2004
Publisher: Jones and Bartlett Publishers, Inc
Country of Publication: US
Dimensions (cm): 15.2 x 22.9  x 1.4
Weight (kg): 0.6